Zach hodgkins biography of albert
Research We Fund
Solu Therapeutics, INC
TAP Partner
Boston, MassachusettsUnited States
A phase 1 study of STX-0712, a CCR2-CyTAC monocyte depletor, in patients with CMML
In December 2024, LLS made an equity investment in Solu Therapeutics to "Support Preclinical and Clinical Development of STX-0712 in hematological malignancies, primarily in CMML."
Solu Therapeutics is a biotechnology company dedicated to developing next-generation therapeutics to eliminate disease-driving cells in cancer, immunology and other therapeutic areas. The company’s proprietary CyTAC (Cytotoxicity Targeting Chimera) and TicTAC (Therapeutic Index Control Targeting Chimera) platforms enable the development of innovative medicines that combine the target-binding capability of small molecules with the therapeutic power of biologics.
STX-0712 is a CyTAC targeting the GPCR CCR2, which is a selective marker expressed at high levels on pathogenic monocytes. Pathogenic monocytes expressing CCR2 have been shown to be the key drivers in some hematological malignancies.
Program:Therapy Acceleration ProgramProject Term:Start Date: December 18, 2024 End Date: February 21, 2025
Jean Koff, MD, MSc
Winship Cancer Institute
Atlanta, GeorgiaUnited States
Translating molecular profiles into treatment approaches to target disparities in lymphoma
Although many patients with diffuse large B-cell lymphoma (DLBCL) are cured with standard therapy, others will die from their disease. Survival is significantly worse for African American (AA) patients and those with Epstein- Barr virus (EBV), which is common in patients from Latin America. The reasons behind these poor outcomes are not well understood, in part because most studies of molecular features in lymphomas have not included enough patients from these racial and ethnic groups.
Lymphoma tumors include not just the cancer cells themselves, but also surrounding cells and proteins that help the cancer cells
Abstract
B7x (B7-H4 or B7S1) is a coinhibitory member of the B7 immune checkpoint ligand family that regulates immune function following ligation with its unknown cognate receptors. B7x has limited expression on normal tissues, but is up-regulated on solid human tumors to inhibit anti-tumor immunity and associates with poor clinical prognosis. We assessed the contribution of cytokine stimuli to induce surface B7x expression on cancer cells and the role of tumor-expressed B7x in a murine pulmonary metastasis model, and finally evaluated the potential interaction between B7x and Neuropilin-1, a suggested potential cognate receptor. We showed that pro-inflammatory and anti-inflammatory cytokines IFNγ, TNFα, and IL-10 did not induce expression of B7x on human or murine cancer cells. Following i.v. injection of CT26, a murine colon cancer cell line in the BALB/c background, we observed a significant increase in tumor burden in the lung of B7x-expressing CT26 mice compared to B7x-negative parental CT26 control mice. This was marked by a significant increase in M2 tumor associated macrophages and antigen-specific CD8 T cell exhaustion. Finally, we found through multiple systems that there was no evidence for B7x and Neuropilin-1 direct interaction. Thus, the B7x pathway has an essential role in modulating the innate and adaptive immune cell infiltrate in the tumor microenvironment with its currently unknown cognate receptor(s).
Keywords: B7x, immune checkpoint, pulmonary metastases, CD8 T cells, innate cells
INTRODUCTION
T cell costimulation and coinhibition are mediated by proteins, notably the B7 ligand and CD28 receptor family of molecules and are critical processes regulating T cell activation, proliferation, and effector function [1, 2]. The B7 ligand and CD28 receptor family of proteins are very well characterized and has seen considerable success and interest in the field of cancer immunology due to their influence in immune evasion. Immune evasion accelera
Zachary Morris, MD, PhD
I am an Associate professor and Chair of the Department of Human Oncology. I am originally from Rockford, IL, and completed my undergraduate studies at Ripon College in Ripon, Wis. After my undergraduate work, I earned two Master’s degrees (Medical Anthropology and History of Science, Medicine, and Technology) at Oxford University as a Rhodes Scholar. I completed my MD at Harvard Medical School and my PhD at Harvard University in the Biological and Biomedical Sciences Program, where I performed thesis research in the laboratory of Prof. Andrea McClatchey.
I completed a preliminary year internship in internal medicine at the University of Hawaii and then completed my residency training in radiation oncology at the University of Wisconsin Hospitals and Clinics. Under the American Board of Radiology’s Holman Pathway, I spearheaded a collaborative research project during my residency in the labs of Prof. Paul Sondel and Prof. Paul Harari.
As a physician-scientist, my current clinical focus is on the treatment of patients with melanoma and soft tissue sarcomas. My independent translational research laboratory focuses on the mechanisms whereby radiation may enhance the response to immunotherapies. I serve as program director for the University of Wisconsin Bentson Research Fellowship and am an active member of ASTRO, ASCO, RSNA, ABS, ACR, AACR, Radiation Research Society, the Society for Immunotherapy in Cancer (SITC) and the NCCN Guidelines expert panel on soft tissue sarcomas.
Dr. Morris's UW Health ProfileEducation
Resident, University of Wisconsin–Madison, Radiation Oncology (2016)
Intern, University of Hawaii, Internal Medicine (2012)
MD, Harvard Medical School, Medicine (2011)
PhD, Harvard University, Biological and Biomedical Sciences (2011)
MSc, Oxford Frances Mary Hodgkins (1869-1947) is arguably New Zealand’s leading expatriate artists. Her works capture the spirit of an era greatly influenced by Impressionism and the beginnings of en plein air painting, Post-Impressionism, Fauvism and two World Wars. Slideshow best viewed At Sunnyside Museum of New Zealand,Frances Hodgkins, biography, https://collections.tepapa.govt.nz/topic/935 (accessed 14 Jan 2019). Excellent biography of Frances Hodgkins Archive of Sold Paintings of Frances Hodgkins Frances Hodgkins at Wikiwand ~SunnysideClick For Enlarged Detail
Video: Jonathan Grant Gallery
Details
Source
Read More
Thanks for Visiting 🙂
Related